InsidersTradesSigma
Track the Aytu Biopharma, INC share price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Aytu Biopharma, INC has published 59 insider filings. Market capitalisation: €23.4m. The latest transaction was reported on 30 July 2026 (Attribution). Among the most active insiders: PYSZCZYMUKA GREG. All data is openly available.
59
Insider Decl.
n/a
Thresholds
€290,223
9 ops.
Buy Volume
n/a
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Aytu Biopharma, INC Strong Buy (bullish), based on 3 analysts. Average price target: US$9.50.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,780 of 29,063 companies
19.5
score / 100
Value7
Quality32
FCF yld-21%
Earn yld-55%
EV/EBITDA·
ROE-97%
Gross mgn69%
Net mgn-20%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 July 2026
Declarations59 total
10,000 shares0Common StockSEC:0001437749-26-025075:0
10,000 shares0Common StockSEC:0001437749-26-025076:0
10,000 shares0Common StockSEC:0001437749-26-025077:0
10,000 shares0Common StockSEC:0001437749-26-025078:0
25,000 shares0Common StockSEC:0001437749-26-025080:0
15,000 shares0Common StockSEC:0001437749-26-025081:0
20,000 shares0Common StockSEC:0001437749-26-025082:0
30,000 shares0Common StockSEC:0001437749-26-025083:0
10,000 shares0Common StockSEC:0001437749-25-030632:0
10,000 shares0Common StockSEC:0001437749-25-030634:0
10,000 shares0Common StockSEC:0001437749-25-030636:0
10,000 shares0Common StockSEC:0001437749-25-030639:0
31,446 shares0Common StockSEC:0001437749-25-030642:0
22,500 shares0Common StockSEC:0001437749-25-030642:1
16,243 shares0Common StockSEC:0001437749-25-030645:0
17,500 shares0Common StockSEC:0001437749-25-030645:1
19,606 shares0Common StockSEC:0001437749-25-030648:0
12,500 shares0Common StockSEC:0001437749-25-030648:1
12,500 shares0Common StockSEC:0001437749-25-030650:0
66,666 shares@ US$1.5034.2% of flowCommon StockSEC:0001437749-25-019956:0
Canonical exit: 7 Sept 2025 (T+90)
16,666 shares@ US$1.50100.0% of flowCommon StockSEC:0001437749-25-019958:0
Canonical exit: 7 Sept 2025 (T+90)
209 sharesCommon SharesSEC:0001437749-25-010224:0
105 sharesCommon SharesSEC:0000912282-25-000223:0
15,000 shares@ US$1.307.3% of flowCommon StockSEC:0001437749-25-005873:0
Canonical exit: 29 May 2025 (T+90)
208 sharesCommon SharesSEC:0000912282-25-000018:0
25 of 59 declarations
关于 Aytu Biopharma, INC
Aytu BioPharma, Inc. 是一家美国专业制药公司，在美国纳斯达克资本市场上市，股票代码为 AYTU。从股票分析师的角度来看，它最好被描述为一家小型商业阶段生物制药公司，结合了品牌处方产品和专注的中枢神经系统 (CNS) 策略。公司总部位于科罗拉多州丹佛市。Aytu 最初于 2002 年注册为 Rosewind Corporation，后于 2015 年在特拉华州重新注册，并于 2021 年更名为 Aytu BioPharma, Inc.。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf)) 当前的战略叙事围绕中枢神经系统药物，特别是重度抑郁症 (MDD) 和多动症 (ADHD)。Aytu 最近最重要的增长动力是 EXXUA (gepirone) 缓释片，这是一种新型首创的选择性血清素 5HT1a 受体激动剂，已获得 FDA 批准用于成人 MDD 患者。公司强调 EXXUA 差异化的临床特征，包括标签中没有性功能障碍警告，这可能有助于其在一个庞大且竞争激烈的美国抗抑郁药市场中定位。2025 年 6 月，Aytu 签订了 EXXUA 在美国的独家商业化协议，随后将该产品作为其商业策略的核心推出。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf)) 除了 EXXUA，Aytu 还保留了传统和支持性产品线，有助于收入多元化。其 ADHD 产品组合包括适用于 6 岁及以上患者的 Adzenys XR-ODT 和 Cotempla XR-ODT。公司还销售 Karbinal，一种用于过敏症状的 12 小时卡比沙明口服混悬液，以及儿科氟化物/维生素处方品牌 Poly-Vi-Flor 和 Tri-Vi-Flor。这些产品使 Aytu 拥有高增长的 CNS 资产和更成熟的儿科/过敏特许经营权的组合。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf)) 竞争定位仍然充满挑战。Aytu 在由大型品牌制药竞争对手主导的治疗领域运营，并且在某些情况下受到仿制药的压力。因此，公司一直在重塑其产品组合，并将资金集中用于商业化而非广泛的临床开发。近期里程碑包括 2025 年 6 月的股权融资、EXXUA 商业化交易、公司在 2025 年末的推出执行，以及 Adzenys 和 Cotempla 的国际商业化安排，包括加拿大。对于法语市场的投资者而言，AYTU 是一家高风险、催化剂驱动的制药公司，其估值可能取决于 EXXUA 的吸收情况、传统产品现金流的保留以及审慎的资本配置。([sec.gov](https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm?utm_source=openai))
